Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
PFE US​

Pfizer Inc(PFE US)

$30.03-0.391.28%Ext:$29.76-0.270.89%(Market Closed · 00:00:05 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Pfizer Inc — Company Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Albert Bourla
Headquarters
New York City, NY, US
IPO Date
Jun 1, 1972
Employees
75,000
Website
www.pfizer.com

Key Metrics

Price
$27.80
Market Cap
$158.44B
Revenue (TTM)
$14.45B
Net Income (TTM)
$2.69B
EPS (TTM)
0.47
P/E (TTM)
21.15
P/B (TTM)
1.76
Dividend Yield
6.70%
ROE (TTM)
2.98%
ROA (TTM)
1.29%
Operating Margin
27.90%
Beta
0.23

Dividends

Last Dividend
$0.43
Last Yield
0.07%

Summary

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Website
www.pfizer.com
Location
New York City, NY, US
Phone212 733 2323
Employees75,000
CEOAlbert Bourla
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJun 1, 1972

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(6.6K)

Expand
  • 4BOURLA ALBERT16 Oct
  • SC 13GTRex Bio, Inc.16 Oct
  • 4BOURLA ALBERT14 Oct
  • 4BOURLA ALBERT1 Oct
  • 4Buckley Mortimer J29 Sep
  • 4Echevarria Joseph29 Sep
  • 4NARAYEN SHANTANU29 Sep
  • 4Quincey James29 Sep
  • 4Taraporevala Cyrus29 Sep
  • 4SMITH JAMES C29 Sep
  • 4BOURLA ALBERT16 Sep
  • 4BOURLA ALBERT1 Sep
  • N-PXAnnual report of proxy voting record31 Aug
  • 3Guegan Cecile28 Aug
  • 4BOURLA ALBERT17 Aug
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug
  • 4BOURLA ALBERT12 Aug
  • 4DAMICO JENNIFER B.6 Aug
  • 4BLAYLOCK RONALD E5 Aug
  • 4Buckley Mortimer J5 Aug

News

  • Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem03:00AM
  • Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip23 Oct
  • Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?23 Oct
  • What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer22 Oct
  • Bristol Myers Squibb vs. Pfizer: Consistency vs.22 Oct
  • Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher22 Oct
  • Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares22 Oct
  • Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing20 Oct
  • Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher20 Oct
  • Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It20 Oct
  • Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?19 Oct
  • 5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings19 Oct
  • Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch19 Oct
  • Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow19 Oct
  • These 5 Dividend Stocks Look Like Income Bargains. The Math Says Otherwise19 Oct
  • $50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year19 Oct
  • Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.18 Oct
  • Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year18 Oct
  • Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?16 Oct
  • Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady16 Oct

Mentions in Filings

  • … g and maintenance. Other significant accomplishments of Mr. Yakov have included establishing an AT&T wholesale e-commerce platform for 180,000 employees and working with high-profile clients such as Disney, Cisco Systems, <strong>Pfizer</strong>, Motorola, and Microsoft, among many others. Mr. Yakov also developed and maintains a complex extranet/intranet infrastructure that allows Doremus, an Omnicom Communication subsidiary, to provide its advertising services …
    OLB GROUP, INC.Pfizer Inc·DEF 14A - Definitive proxy statement·Q4 26·23 Oct
  • … as a member of the board of directors of Lyell Immunopharma, Inc., a biotechnology company, since May 2020. Mr. Rieflin previously served as a member of the board of directors of Anacor Pharmaceuticals, Inc. (acquired by <strong>Pfizer</strong> Inc.), a biotechnology company, from April 2011 to July 2016, RAPT Therapeutics, Inc. (acquired by GlaxoSmithKline plc), a biotechnology company, from May 2015 to January 2025, Flexus Biosciences, Inc. (acquired by Bristo …
    Lycia Therapeutics, Inc.Pfizer Inc·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·23 Oct
  • … such as Amgen Inc., Apogee Therapeutics, Inc. (acquired by AbbVie Inc.), AstraZeneca plc, Belenos Biosciences Inc., Generate Biomedicines, Inc., GSK plc, Johnson & Johnson, KeyMed Biosciences Inc., Eli Lilly and Company, <strong>Pfizer</strong> Inc., Sanofi S.A., and Upstream Bio, Inc. that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also inclu …
    WINDWARD BIO GROUP AGPfizer Inc·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • … ed to explore different routes of administration of efti in solid tumors. In September 2018, the investigator-initiated “INSIGHT” clinical trial was amended through a collaboration with Merck KGaA, Darmstadt, Germany and <strong>Pfizer</strong>, Inc. IKF was the sponsor of the amended Phase I clinical trial (called INSIGHT-004) conducted under the existing protocol of the ongoing INSIGHT clinical study. The new collaborative study tested the safety and efficacy …
    IMMUTEP LtdPfizer Inc·20-F - Annual report (foreign private issuer) FY 2026·FY26·23 Oct
  • … njugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and <strong>Pfizer</strong>. For more information, please visit www.BioNTech.com. --- BioNTech Forward-Looking Statements
    BioNTech SEPfizer Inc·EX-99.1 - 6-K - Current report (foreign private issuer)·Q4 26·22 Oct
  • … t of cHBV infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against <strong>Pfizer</strong> Inc., BioNTech SE, and certain of their affiliates, for use of Arbutus’ patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com. **About AB-101** AB-101 is an oral PD-L1 inhibi …
    Arbutus Biopharma CorpPfizer Inc·EX-99.1 - 8-K - Other Events·Q4 26·22 Oct

Key Stats

Trading

Px/Chg 1D$27.80 / -1.14%
Prev Close$28.81
% of 52Wk H97.40%
Avg Volume39.04M
Beta0.23
Mkt Cap158.44B
FD Mkt Cap162.15B

Float

Shrs Out/Float5.70B / 5.69B
Short Float0.03%
Days to Cover2.69
Stock Repurchased$0.00

Current Valuation

EV221.50B
EV/EBITDA13.23
EV/Sales3.50
P/B1.76
P/S2.50
FCF Yield1.38%
ROE2.98%
ROA1.29%
Current Ratio1.25

Dividend

Cash$0.43
Yield6.70%
Yield (TTM)6.70%

Estimates

P/E21.15
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings13.146.8873.4717.09-90.6958.95
Price / Sales5.282.152.632.158.5110.96
Price / Book Value1.802.261.761.521.731.76
Price / Free Cash Flow32.168.2932.6913.9433.1872.71
ENTERPRISE VALUE METRICS
Enterprise Value222,044.9250,494.8224,972.1197,228.8216,029.6221,499.4
Enterprise Value / Sales7.402.503.783.1012.3015.33
Enterprise Value / EBITDA74.086.1123.5410.88285.7544.11
Enterprise Value / EBIT-16.156.9668.8617.75-232.0457.71

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-6.3%81,288.0100,330.059,553.063,627.062,579.0
Gross Income-1.6%46,875.062,090.030,340.041,846.044,014.0
EBITDA-16.3%30,793.041,031.09,557.018,127.015,096.0
EBIT-20.6%25,602.035,967.03,267.011,114.010,191.0
Net Income-23%22,147.031,365.02,133.08,020.07,770.0
EPS (Diluted)-23.1%3.885.470.371.411.36
BALANCE SHEET
Cash & ST Inv-18.7%31,069.022,732.012,690.020,477.013,596.0
Total Assets3.5%181,477.0197,206.0226,501.0213,396.0208,160.0
Total Liabilities3.9%104,014.0101,289.0137,213.0124,899.0121,385.0
Total Shareholder Equity2.9%77,201.095,661.089,014.088,203.086,476.0
CASH FLOW
Net Operating Cash Flow-22.6%32,580.029,267.08,700.012,744.011,705.0
Cap Ex-76.5%-2,711.0-3,236.0-3,907.0-2,909.0-2,629.0
Free Cash Flow-25.8%29,869.026,031.04,793.09,835.09,076.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)30.06
Basic Shares5,699.44
Market Cap171,296.7
Diluted Shares5,731.00
Fully Diluted Shares Outstanding5,731.00
Fully Diluted Market Cap172,245.2
+Consolidated Debt64,455.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,703.0
−Short-term Investments-11,372.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest303.0
+Pension Liabilities—
Enterprise Value234,351.7

Segment data

Revenue

by Products and services

  • Biopharma Segment98%
  • Segment Reporting, Reconciling Item, Corporate Nonsegment2%

Revenue

by Geography

  • United States59%
  • Developed Rest Of World26%
  • Emerging Markets15%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US